Brii Biosciences Limited (BRIBF) Stock Price & Analysis
Brii Biosciences Limited (BRIBF) — price $0.13 (0.00%), as of the Nov 20, 2026 trading session; market cap $93.4M.
Educational signal · not a buy or sell recommendation · How to read this
Brii Biosciences Limited · BRIBF
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases and central nervous system disorders.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.13 | |
| Change on the day | 0.00% | |
| Market capitalisation | $93.4M | — |
| Shares traded on the day | 4.2K |
Price & events
Other perspectives
Council score for Brii Biosciences (BRIBF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Brii Biosciences (BRIBF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Brii Biosciences Limited (BRIBF) is the company analyzed here. It employs 80 people. In Q4 FY2025 it reported revenue of CN¥18M and net income of -CN¥143M. The market values it at $93.4M.
What do the latest results show for Brii Biosciences (BRIBF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of CN¥18M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | CN¥18M | -CN¥143M | -CN¥0.10 (diluted) |
| Q2 FY2025 | CN¥496,500 | -CN¥74M | -CN¥0.10 (diluted) |
| Q4 FY2024 | CN¥14M | -CN¥114M | -CN¥0.16 (diluted) |
What are the financial strengths and risks for Brii Biosciences (BRIBF)?
Short answer · as of
The distress and quality screens read Altman Z 10.73 · Piotroski F 3. Trailing ratios: ROE -7.3% · ROA -7.6% · current ratio 52.24 · earnings yield -25.9% · free-cash-flow yield -38.8%.
Data-derived red flags
- Negative return on equity (-7.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Brii Biosciences (BRIBF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $310.26M · EPS -0.45 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $310.26M
- EPS estimate
- $-0.45
Measured against a quoted price of $0.13 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BRIBF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BRIBF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Brii Biosciences Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the BRIBF research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BRIBF a good stock to buy?
Stock Expert AI does not rate BRIBF buy, sell or hold. Brii Biosciences Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BRIBF stock price today?
The last price recorded for Brii Biosciences Limited (BRIBF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for BRIBF?
Brii Biosciences Limited faces several risks, including high operational costs that contribute to negative profit margins, which may impact its financial sustainability.
What are the key factors to evaluate for BRIBF?
Evaluate BRIBF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does BRIBF data refresh on this page?
BRIBF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BRIBF's recent stock price performance?
Brii Biosciences Limited (BRIBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting significant health challenges. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BRIBF overvalued or undervalued right now?
Brii Biosciences Limited (BRIBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BRIBF before investing?
Before investing in Brii Biosciences Limited (BRIBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com